BT-11 is primarily used in research settings for its selective activation of the nuclear receptor RORγt, which plays a key role in the differentiation of T helper 17 (Th17) cells. Due to this action, BT-11 has shown promise in preclinical studies for modulating immune responses, particularly in models of inflammatory and autoimmune diseases such as multiple sclerosis, psoriasis, and inflammatory bowel disease (IBD). Its ability to locally suppress pathological inflammation in the gut without causing systemic immunosuppression makes it a candidate for targeted therapies in gastrointestinal disorders. BT-11 is not used clinically and remains an investigational tool compound in immunology and drug development.